Multiples PE Invests INR 6,850 Mn in BDR Pharma for 9.3% Stake BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments. Its portfolio in India includes Covid-19 drugs Favipiravir, Molnupiravir and Baricitinib

By Soumya Duggal

Opinions expressed by Entrepreneur contributors are their own.

You're reading Entrepreneur India, an international franchise of Entrepreneur Media.


Mumbai-based Multiples Private Equity-led consortium invests INR 6,850 Mn for a ~9.3% stake in BDR Pharmaceuticals International Private Limited, an R&D-focused, integrated pharma player.

Multiples has been a regular investor in Pharmaceuticals and Healthcare space, says the company. It is the first private equity (PE) investor in BDR Pharma. The latter focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology.

BDR Pharma's Chairman and MD, Dharmesh Shah said, "We are looking forward to accelerating our growth journey with trusted investors having a deep understanding of the sector, and regulatory environment and who bring first-hand experience in working with innovative, high-growth companies."

The consortium of investors participating along with Multiples includes institutional investors such as the investment arm of Times Group, QRG Invest (Havells Family Office), and high net worth individuals Nishant Agarwal of Avighna Group, and Mallika Srinivasan of TAFE.

The funds will be used by the company to build additional research and development capabilities in current and emerging areas, accelerate investments in manufacturing capacity expansion and enhance the degree of vertical integration. The Company will also selectively pursue inorganic opportunities to build scale.

"Multiples brings strong sector expertise with investments in companies across the value chain. Animal health (Zenex Animal Health), Formulations (Encube and Natco Pharma) and Hospitals (Vikram Hospitals) are some of the segments where it has backed companies with strong differentiation, and high-quality entrepreneurs and management teams," says an official statement.

The firm sees Pharmaceuticals and Healthcare as a highly promising segment in the country, with Indian companies having capabilities to serve a growing domestic market as well as be competitive in global markets. Multiples expect this sector to be a highly active sector for us in the future as well.

Soumya Duggal

Former Feature Writer

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Related Topics

Business News

Former Pediatrics Professor Donates $1 Billion, Makes Albert Einstein College of Medicine Tuition-Free

Dr. Ruth Gottesman's husband left her $1 billion in Berkshire Hathaway stock with the following instructions: "Do whatever you think is right with it."

News and Trends

Merak Ventures Invests USD 1.45 Mn in Agri-food Startup Farmtheory

The investment will enable Farmtheory to scale its operations, mainly focusing on expanding its supply arm.

News and Trends

Shadowfax Secures USD 100 Mn in Series E Led by TPG NewQuest

The Bengaluru-based startup aims to utilise the raised funds to reinforce its middle-mile network and extend its last-mile delivery services to cover all 20,000 pin codes across India.

Business Ideas

55 Small Business Ideas to Start in 2024

We put together a list of the best, most profitable small business ideas for entrepreneurs to pursue in 2024.

Social Media

With This LinkedIn Algorithm Change, Your Best Posts Could Reach New Readers for Years

It's one of many new features rolling out on the platform in 2024.

News and Trends

Renewables Energy Focused InSolare Raises INR 66 Cr Led by Negen Capital

The Bengaluru-based startup aims to use the raised funds to further improve its capabilities and accelerate its impact in the renewable energy sector.